Posts by: Forest Ray

Forest Ray

Forest Ray received his PhD in systems biology from Columbia University, where he developed tools to match drug side effects to other diseases. He has since worked as a journalist and science writer, covering topics from rare diseases to the intersection between environmental science and social justice. He currently lives in Long Beach, California.

December 11, 2020December 11, 2020

Trusted Sources May Help Ease COVID-19-related Anxiety in MG Patients, Survey Reveals

News

People with myasthenia gravis (MG) felt high anxiety regarding COVID-19, experienced changes in their interactions with healthcare systems, and generally trust information coming from non-presidential federal government sources and ... Read more

November 24, 2020November 24, 2020

App-Based Study Launched to Gain Better Understanding of Myasthenia Gravis

News

UCB Biopharma and doc.ai have launched a digital trial aimed at improving the speed and accuracy of diagnosis and predicting symptom flares in myasthenia gravis (MG) patients by recognizing ... Read more

November 20, 2020November 20, 2020

Three Share Their Life With MG in Online Documentary Series, ‘A Mystery to Me’

News

Three people living with myasthenia gravis (MG) tell their stories in the three-part online documentary series “A Mystery to Me,” available from MG United, a patient-focused platform operated by ... Read more

November 10, 2020November 11, 2020

Melatonin Supplements May Worsen MG Symptoms, Case Series Suggests

News

Melatonin supplements usually used to treat insomnia may aggravate the symptoms of myasthenia gravis (MG), possibly by activating the immune system or by interacting with other medications used to ... Read more

October 27, 2020October 27, 2020

App-based MyRealWorld MG Study Seeks Patient Insights

News

Argenx is looking for participants in an app-based international study of the impact and burden of myasthenia gravis (MG) on patients and their families. The company has released an app ... Read more

October 13, 2020October 13, 2020

1st Participant Dosed in Phase 1/2a Trial Testing Potential MG Therapy NMD670

News

The first participant has been dosed in a Phase 1/2a trial evaluating NMD670, NMD Pharma‘s investigational therapy for myasthenia gravis (MG). “I am pleased to announce that our lead ... Read more

September 2, 2020September 2, 2020

Same But Different Photo Contest Celebrates People With Rare Diseases

News, syndicated

Same But Different, a U.K. nonprofit that uses the arts to bring communities together, is holding a calendar photography competition to raise awareness for rare diseases. Under the theme ... Read more

August 24, 2020August 24, 2020

Xperiome Platform Aims to Streamline Searches for Rare Diseases, Gain Patient Input

News, syndicated

Raremark, an online rare disease patient community, has launched a digital platform called Xperiome, aimed at streamlining the search for new medicines for rare disorders and incorporating more patient ... Read more

July 21, 2020July 21, 2020

Stress and Depression Linked With Relapses in MG Patients

News

Stress and depression are associated with higher relapse rates in people with myasthenia gravis (MG), according to a recent study. Attention to evidence of either disorder is important for ... Read more

July 13, 2020July 13, 2020

National Survey Seeks to Assess Full Social, Economic Burdens of Rare Diseases in US

News, syndicated

The EveryLife Foundation for Rare Diseases has launched a nationwide National Burden of Rare Disease Survey to measure the full implications, economic and social, of living with rare disease ... Read more